Understanding the psychological blocks in medicine-taking: how pharma can help
Medicines adherence remains a massive problem for healthcare systems, the pharmaceutical industry and patients, leading to increased disease burden and personal risks. In this new white paper, Hannah Gagen looks beyond traditional approaches into the psychology behind adherence to understand the real challenges and solutions.
The major focus for the pharmaceutical industry is market access – making sure that novel medicines make it through the clinical and cost barriers to reach patients. But even once this has been surmounted a potentially bigger hurdle exists – adherence. Failing to take medicines as prescribed is expensive for healthcare systems and pharma, plus potentially damaging, or even life-threatening, for patients.
Despite numerous attempts to tackle non-adherence, it remains a significant challenge. But perhaps we are not looking at solutions the right way? Here, Hannah Gagen, from Boehringer Ingelheim, challenges traditional solutions and takes a more in-depth look at the psychological factors behind this problem and how they can inform new approaches that underpin a more collaborative resolution between doctors, patients and the pharmaceutical industry
Read this white paper from Boehringer Ingelheim to understand:
• Key definitions and metrics around medicines non-adherence
• Factors underlying intentional and non-intentional non-adherence
• Expert views on the psychology of adherence
• How pharma needs a new collaborative approach to tackling adherence
Click on the ‘Download the white paper’ button now to obtain your free copy.
For more information on Boehringer Ingelheim Ltd please visit: